Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TROPIC trial (cabazitaxel): what clinicians have said so far
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
- NCT00417079 ↗
- Completed
- Sanofi
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on TROPIC (cabazitaxel in metastatic castration-resistant prostate cancer after docetaxel treatment) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TROPIC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 posts on X | |
| 7 podcast episodes | |
| 3 YouTube videos |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Neoplasms; Prostatic Neoplasms
- Interventions
- cabazitaxel (XRP6258) (RPR116258); mitoxantrone; prednisone
- Arms
- Mitoxantrone + Prednisone · Active comparator
- Cabazitaxel + Prednisone · Experimental
- Enrollment
- 755
- Primary outcomes
- Overall Survival
- Sponsor
- Sanofi
- Start
- Jan 2007
- Primary completion
- Sep 2009
- Results posted
- Yes
- Registry record
- NCT00417079 · updated Mar 10, 2011
Publications
linked from the registry- Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015 Apr;26(4):750-755. doi: 10.1093/annonc/mdu587. Epub 2014 Dec 23. PubMed 25538172
- Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I, Gravis G, Devin J, Shen L, de Bono JS, Sartor AO; TROPIC Investigators. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013 Sep;24(9):2402-8. doi: 10.1093/annonc/mdt194. Epub 2013 May 30. PubMed 23723295
- Pouessel D, Oudard S, Gravis G, Priou F, Shen L, Culine S. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. Bull Cancer. 2012 Jul-Aug;99(7-8):731-41. doi: 10.1684/bdc.2012.1608. French. PubMed 22743148
- de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. PubMed 20888992